1. Use of the following therapies:

* Etanercept in the 4 weeks prior to the baseline visit (Day 1)

* Adalimumab in the 8 weeks prior to the baseline visit (Day 1)

* Infliximab in the 12 weeks prior to the baseline visit (Day 1)

* Any other investigational biologics in the 8 weeks prior to the baseline visit (Day 1)

* Leflunomide in the 4 weeks prior to the baseline visit (Day 1) • Thalidomide in the 4 weeks prior to the baseline visit (Day 1)

* Cyclosporine in the 4 weeks prior to the baseline visit (Day 1)

* I.V. immunoglobulin (I.V. Ig) in the 8 weeks prior to the baseline visit (Day 1)

* 6-Mercaptopurine, azathioprine, cyclophosphamide, or chlorambucil in the 12 weeks prior to the baseline visit (Day 1)

* Colchicine, dapsone, mycophenolate mofetil \& systemic antibiotics in the 3 weeks prior to the baseline visit (Day 1)

* Corticosteroids "20mg/day or \>0.4 mg/kg, whichever applies, in the 1 week prior to the baseline visit (Day 1)

2. history of immunocompromise including HIV infection

3. positive Hep B surface antigen -

Anakinra as a Treatment for Hydradenitis Suppurativa